I-41 Marylore Chenel Developing an In Vitro – In Vivo Correlation Model Using a Population Approach in NONMEM Wednesday 10:15-11:45 |
I-47 Jae Yong Chung Modelling of Atorvastatin Pharmacokinetics in relation to SLCO1B1 genotype and Simulations for Bioequivalence Study Wednesday 10:15-11:45 |
I-57 Willem de Winter Dynamics of a Two-Receptor Binding Model: How Affinities and Capacities Translate into Long- and Short-Term Behaviour and Physiological Corollaries Wednesday 10:15-11:45 |
I-59 Ivan Demin Longitudinal model-based meta-analysis in rheumatoid arthritis: an application towards model based drug development Wednesday 10:15-11:45 |
I-61 Vincenzo Luca Di Iorio Application of Stochastic Differential Equations to Disease Progression in a Neuropathic Pain Model in Rats Wednesday 10:15-11:45 |
II-02 Anne Dubois Pharmacokinetic bioequivalence analysis of biologics using nonlinear mixed effects modeling Wednesday 14:55-16:10 |
II-03 Anne Dubois Clinical trial simulations to design a crossover study assessing the equivalence on the pharmacodynamic surrogate marker between an immediate and a modified release formulations Wednesday 14:55-16:10 |
II-10 Charles Ernest Multinomial Markov-chain model of sleep architecture in Phase-Advanced Subjects (PAS) Wednesday 14:55-16:10 |
II-15 Martin Fink Diversity: Academia-Industry Collaborations on Modeling and Simulation to enhance Scientific Capability Development – The Novartis Experience Wednesday 14:55-16:10 |
II-21 Sathej Gopalakrishnan Population PK/PD evaluation of the effect of dienogest on Hoogland Score in young healthy women Wednesday 14:55-16:10 |
II-37 Manish Gupta Application of Two-Target Quasi-Steady-State (QSS) Model in Population Pharmacokinetic and Pharmacodynamic (PK-PD) Modeling of MNRP1685A in Cynomolgus Monkeys Wednesday 14:55-16:10 |
II-38 Serge Guzy Optimizing The Entire Drug Development Process Using Pharmacometric Tools: From Preclinical To Marketing Wednesday 14:55-16:10 |
II-50 Candice Jamois Title Pharmacokinetic-Pharmacodynamic Modeling of the Relationship between Aleglitazar Exposure and Lipids Response in Type 2 Diabetes Patients. Wednesday 14:55-16:10 |
II-51 Hyewon Jeon A Population Pharmacokinetic/pharmacodynamic Approache of Drug X in Healthy Korean Wednesday 14:55-16:10 |
II-59 Thomas Kerbusch Phase 2b dose selection for the treatment of autoimmune disorders leveraging comparator data Wednesday 14:55-16:10 |
III-13 Lay Ahyoung Lim Development of a longitudinal model for characterizing adverse events of psychiatric drugs in routine clinical care Thursday 09:50-11:05 |
III-22 Hugh McDevitt Technology Roadmap to Support Model Based Drug Development Thursday 09:50-11:05 |
III-27 Enrica Mezzalana Title: Quantitative Assessment of First Night Effect in a Polysomnographic Insomnia Study through a Multinomial Mixed-Effect Markov-Chain Model Thursday 09:50-11:05 |
III-31 Flora Musuamba-Tshinanu KPD modelling of trough FEV1 in chronic obstructive pulmonary disease (COPD). Thursday 09:50-11:05 |
III-44 Zinnia Parra-Guillen Target Mediated Drug Disposition Model to Describe the Expression and Kinetics of IL12 And IFNγ in Gene Therapy Thursday 09:50-11:05 |
III-52 Olivier Petricoul From Animal to Human with a new monoclonal antibody: An example of the use of pharmacokinetics only to assist on the choice of first in human dose. Thursday 09:50-11:05 |
III-57 Gregory Pinault A structured approach to industrialize the data sourcing to support model based drug development Thursday 09:50-11:05 |
III-65 Martijn Ruppert Population PK/PD Modeling of a Hepatitis C NS3 Inhibitor Thursday 09:50-11:05 |
IV-02 Tarjinder Sahota Parameterisation of biomarker response in the assessment of long term safety Thursday 15:05-16:20 |
IV-07 Yi SoJeong Population Pharmacokinetics of a Novel Proton Pump Inhibitor, Drug Y, in Healthy Volunteers Thursday 15:05-16:20 |
IV-13 Andreas Steingoetter A population pharmacokinetic model for Gd-DTPA in DCE-MRI Thursday 15:05-16:20 |
IV-22 David Ternant Influence of the FcγRIIIa genetic polymorphism on the effect of antithymocyte globulins on lymphocyte populations in kidney transplantation Thursday 15:05-16:20 |
IV-26 Dorota Tomalik-Scharte Evaluation of Circadian Rhythms in Hepatic CYP3A4 Activity Using Population Pharmacokinetics of Midazolam Thursday 15:05-16:20 |
IV-32 Pavan Vajjah Effect of decontamination on the pharmacokinetics and pharmacodynamics of venlafaxine in overdose Thursday 15:05-16:20 |
IV-49 Pawel Wiczling Pharmacokinetics and Pharmacodynamics of Propofol in ASA III Patients Undergoing Abdominal Aortic Surgery Thursday 15:05-16:20 |
IV-52 Dan Wright Development of a Bayesian forecasting method for warfarin dose individualisation Thursday 15:05-16:20 |
IV-53 Rujia Xie Model based meta-analysis (MBMA) to support the development of decision criteria in dental pain studies Thursday 15:05-16:20 |
IV-55 Shuying Yang Predicting long term Placebo response based on short term observations:Meta-Analysis on FEV1 Response in Asthma Trials Thursday 15:05-16:20 |